Cover
Vol. 2 No. 2 (2024)

Published: August 31, 2024

Pages: 8-17

Original Article

Design, Molecular Docking and ADME Studies of New Imidazolidine Derivatives

Abdullah S. Rashid 1 Ghadeer M. Arzouki Mohammed Q. Hassan Saad R . Mohammed Moamel k. Hussein Ghaith W. Saadi Asmaa A. Abdulnabi
1Department of Pharmacutical Cemistry, College of pharmacy, Al-Nahrain University, Baghdad, Iraq
History
  • Received: June 30, 2024
  • Available Online: August 31, 2024

Abstract

The protective reaction of an organism to potentially harmful stimuli is known as inflammation, and it can result from a variety of sources, including physical, chemical, or viral injuries. A large number of people in our society suffer from long-term inflammatory diseases, which makes it necessary to constantly develop new anti-inflammatory drugs. The development of powerful anti-inflammatory medications has advanced significantly in recent years. As a result, heterocyclic compounds made up a sizeable fraction of organic chemistry due to their pharmacological activity and distinct physical traits that distinguished them from other cyclic compounds. One of the most common N-based heterocyclic molecules is imidazolidine. Numerous scientists have become interested in it because of the variety of industrial and pharmacological uses. In the present study, the work dedicated to designed new imidazolidine derivatives. Molecular Docking Software (Schrodinger) was used to check the binding interaction between new derivatives (4N, 4M, 4D, 4In, 4Ib) and the cyclooxygenase active site of COX-2 in comparison with naproxen, mefenamic acid, diclofenac, indomethacin and ibuprofen as references drugs respectively. The results demonstrated that good binding affinity achieved by all new compounds with the exception of 4D derivative in comparison with diclofenac. Finally, the findings of the ADME study demonstrated that all new derivatives met the Lipinski rule of five and expected to be highly absorbed from gastrointestinal tract.

Keywords

References

  1. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020;180:114147.
  2. Chahal S, Rani P, Kiran, Sindhu J, Joshi G, Ganesan A, et al. Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective. ACS Omega. 2023;8(20):17446–98.
  3. Khan H, Sharma K, Kumar A, Kaur A, Singh TG. Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury. Inflamm Res. 2022;71(3):277–92.
  4. Khan HY, Parveen S, Yousuf I, Tabassum S, Arjmand F. Metal complexes of NSAIDs as potent anti-tumor chemotherapeutics: Mechanistic insights into cytotoxic activity via multiple pathways primarily by inhibition of COX–1 and COX–2 enzymes. Coord Chem Rev. 2022;453:214316.
  5. Miciaccia M, Belviso BD, Iaselli M, Cingolani G, Ferorelli S, Cappellari M, et al. Three-dimensional structure of human cyclooxygenase (h COX)-1. Sci Rep. 2021;11(1):4312.
  6. Vishwakarma RK, Negi DS. The development of COX-1 and COX-2 inhibitors: a review. Int J Pharm Sci Res. 2020;11(8):3544.
  7. Sohail R, Mathew M, Patel KK, Reddy SA, Haider Z, Naria M, et al. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) and gastroprotective NSAIDs on the gastrointestinal tract: a narrative review. Cureus. 2023;15(4).
  8. Chandrasekaran B, Abed SN, Al-Attraqchi O, Kuche K, Tekade RK. Computer-aided prediction of pharmacokinetic (ADMET) properties. In: Dosage form design parameters. Elsevier; 2018. p. 731–55.
  9. Escudero D, Laurent AD, Jacquemin D, Leszczynski J. Handbook of computational chemistry. 2015;1–2381.
  10. Reddy KA, Ashma M, Jyothi V, Jyostna TS. Molecular Properties Prediction of Phenothiazine Derivatives by Using Swiss ADME, PkCSM, Lazar and Protox. World J Pharm Sci. 2019;65–71.
  11. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2(4):541–53.
  12. Chen X, Li H, Tian L, Li Q, Luo J, Zhang Y. Analysis of the physicochemical properties of acaricides based on Lipinski’s rule of five. J Comput Biol. 2020;27(9):1397–406.
  13. Mishra S, Dahima R. In vitro ADME studies of TUG-891, a GPR-120 inhibitor using SWISS ADME predictor. J Drug Deliv Ther. 2019;9(2-s):366–9.
  14. Meng X-Y, Zhang H-X, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7(2):146–57.
  15. Wang G, Zhu W. Molecular docking for drug discovery and development: a widely used approach but far from perfect. Future Med Chem. 2016;8:1707–10.